Characterizing the Fate of Anti‐CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma
Journal of Extracellular Vesicles · 2026-06 · 15 (6)
DOI: 10.1002/jev2.70325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 17.06.2026. Verfasst von Michiel De Coster und 13 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology Research Center (TORC), Team Hematology and Immunology (HEIM), Vrije Universiteit Brussel, Brussels, Belgium. Hauptthemen laut MEDLINE: Extracellular Vesicles, Multiple Myeloma, Single-Domain Antibodies. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kom Op Tegen Kanker, Vrije Universiteit Brussel, Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are promising delivery vehicles capable of transporting therapeutic agents across biological barriers. However, native EVs primarily accumulate in liver, spleen and lungs, limiting targeted delivery to disease sites. To enhance their targeting efficiency for the plasma cell cancer multiple myeloma (MM), localized in the bone marrow (BM), we engineered HEK293‐derived EVs to display a nanobody (Nb) against the MM cell surface marker CS1. We confirmed enrichment of the Nb construct on engineered EVs and binding of α‐CS1 EVs to CS1. In vitro , we found enhanced α‐CS1 EV uptake by MM cell cultures. In vivo , we first compared the biodistribution of HEK293‐derived native EVs in healthy and MM‐bearing mice. Although native EVs reached the BM in both groups, MM‐bearing mice showed increased liver and lung accumulation together with reduced BM delivery. α‐mCS1 EV delivery to the BM of MM‐bearing mice was only slightly increased compared to native EVs, while off‐target accumulation also increased. At the cellular level, no changes in EV delivery to MM cells were detected. In conclusion, while CS1 targeting enhances in vitro EV uptake by MM cells, in vivo biodistribution remains suboptimal. Further optimization is needed to improve EV‐based drug delivery for MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Oncology Research Center (TORC), Team Hematology and Immunology (HEIM), Vrije Universiteit Brussel, Brussels, Belgium.
- Laboratory for Extracellular Vesicle Research, Department of Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium.
- Molecular Imaging and Therapy Research Group (MITH), Vrije Universiteit Brussel, Brussels, Belgium.
- Équipe Labellisée Ligue 2018, INSERM 1068, CNRS 7258, Institut Paoli Calmettes, Centre de Recherche en Cancérologie de Marseille, Aix Marseille Université, Marseille, France.
ORCID-Profile: Lukas Hyka, Pascale Zimmermann, Elke De Bruyne
Förderung
- Kom Op Tegen Kanker
- Vrije Universiteit Brussel
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
De Coster, M., Hyka, L., De Cock, S., Meeussen, S., Wang, Z., Tu, C., Hernot, S., Devoogdt, N., David, G., De Veirman, K., Vanderkerken, K., Menu, E., Zimmermann, P., & De Bruyne, E. (2026). Characterizing the Fate of Anti‐CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma. Journal of Extracellular Vesicles, 15(6). https://doi.org/10.1002/jev2.70325
Vancouver
De Coster M, Hyka L, De Cock S, Meeussen S, Wang Z, Tu C, et al. Characterizing the Fate of Anti‐CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma. Journal of Extracellular Vesicles. 2026;15(6). doi:10.1002/jev2.70325
BibTeX
@article{DeCoster2026,
author = {De Coster, Michiel and Hyka, Lukas and De Cock, Sophie and Meeussen, Sofie and Wang, Zuowei and Tu, Chenggong and Hernot, Sophie and Devoogdt, Nick and David, Guido and De Veirman, Kim and Vanderkerken, Karin and Menu, Eline and Zimmermann, Pascale and De Bruyne, Elke},
title = {Characterizing the Fate of Anti‐CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma},
journal = {Journal of Extracellular Vesicles},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/jev2.70325}
}
EUVIMED